An interventional study of Physical activity in Prostate Cancer, Physical Activity and Hypoxia, sponsored by University Hospital of North Norway. Terminated at 1 site in Norway. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.
Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Treatment
Among 85 studies in Prostatic Neoplasms with a site in Norway — 16 open to participants now, 27 under way, 9 of them phase 3. Prostatic Neoplasms · Norway.
Among the 85 studies in Prostatic Neoplasms with a site in Norway, this one is the 65th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2018, is one of 23 with no phase, and was the 51st registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
Browse Prostatic Neoplasms studies →16 of the 85 studies in Prostatic Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
Norwegian University of Science and Technology · Sites in Norway
Bayer · Sites in Norway, Belgium, Finland and 13 more countries
Merck Sharp & Dohme LLC · Sites in Norway, United States, Argentina and 32 more countries
University of Alberta · Sites in Norway, United States, Canada and 2 more countries
University Hospital of North Norway · Sites in Norway
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 24 · Phase 4 1
First in 1995; this study’s year is marked. 4 started in 2018.
This study's enrollment of 1 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 383 across the 66 interventional studies, 641 across the 18 observational. Of the 53 that completed or were terminated, 17 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 85 have an industry lead sponsor. The 10 most frequent:
University Hospital of North Norway is the lead sponsor of 152 studies on the registry; 24 are open to participants now.
University Hospital of North Norway has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Prostatic Neoplasms with a site in Norway that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT06935487Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection | 2026-12 |
| NCT06172478Daiichi SankyoA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | 2027-09-01 |
Among the 85 studies in Prostatic Neoplasms with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Previous research into metabolic and hypoxic markers has found evidence of preclinical impact of exercise on prostate tumor blood flow and oxygenation in rodents . As radiotherapy is a frequently used and effective therapy for and that sufficient oxygenation is decisive to the effect of radiotherapy, an underlying hypothesis that aerobic exercise might improve treatment efficacy of radiotherapy in prostate cancer is put forward. This study has a potential challenging intervention, but a potential very high gain as it includes active patient participation to significantly improve outcome of radical radiotherapy.
A randomized controlled trial with four to five weeks of moderate/high intensity aerobic exercise program compared with no intervention for 32 prostate cancer patients waiting for radical prostatectomy at the University Hospital of North Norway (UNN). 16 patients will undergo the intervention. The expression of the hypoxic marker pimonidazole in the prostate specimens of intervention groups and the control groups will be assessed. This method is considered a reliable tissue oxygenation measurement technique. These patients will also have their and blood flow and hypoxia measured in prostate cancers through magnetic resonance imaging (MRIs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to the intervention like;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
Other: Physical activity
These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
Aerobic physical activity as stated in Arm A
Hypoxic fraction-gold standard
We will measure the hypoxic fraction in prostate cancer specimens by pimonidazole
Time frame: through study completion, an average of 1 year
Side effects
We will use the Expanded Prostate Cancer Index Composite (EPIC) designed to evaluate patient function and side effects after PC treatment in both groups
Time frame: through study completion, an average of 1 year
Hypoxic fraction-MRI
We will try to explore the hypoxic fraction by use of magnetic resonance imaging
Time frame: through study completion, an average of 1 year
Health related Quality of life
We will use EORTC-QLQ30 which is a validated instrument designed to measure quality of life in prostate cancer in both groups
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Jan 2023, 56 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of North Norway →